Wall Street brokerages expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to post $51.43 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $49.70 million and the highest estimate coming in at $53.00 million. Vanda Pharmaceuticals reported sales of $44.28 million in the same quarter last year, which indicates a positive year-over-year growth rate of 16.1%. The business is scheduled to issue its next earnings report on Wednesday, February 13th.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year sales of $191.47 million for the current year, with estimates ranging from $189.70 million to $193.00 million. For the next year, analysts forecast that the company will report sales of $253.30 million, with estimates ranging from $229.00 million to $292.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.18. The company had revenue of $49.13 million for the quarter, compared to the consensus estimate of $49.44 million. Vanda Pharmaceuticals had a net margin of 7.06% and a return on equity of 5.88%. The firm’s revenue was up 18.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.03) EPS.
Several research analysts recently commented on the stock. Stifel Nicolaus set a $36.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, December 3rd. Jefferies Financial Group raised their price target on shares of Vanda Pharmaceuticals from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday. Oppenheimer reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, December 3rd. Citigroup raised their target price on shares of Vanda Pharmaceuticals from $31.00 to $47.00 and gave the company a “buy” rating in a research report on Friday. Finally, Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research report on Tuesday, November 6th. Eight analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $37.38.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN increased its position in Vanda Pharmaceuticals by 396.9% during the 3rd quarter. Wells Fargo & Company MN now owns 652,305 shares of the biopharmaceutical company’s stock valued at $14,971,000 after purchasing an additional 521,040 shares during the period. Renaissance Technologies LLC grew its position in shares of Vanda Pharmaceuticals by 2.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,681,250 shares of the biopharmaceutical company’s stock worth $32,028,000 after buying an additional 41,200 shares during the last quarter. BlackRock Inc. grew its position in shares of Vanda Pharmaceuticals by 16.3% in the 2nd quarter. BlackRock Inc. now owns 4,960,924 shares of the biopharmaceutical company’s stock worth $94,506,000 after buying an additional 693,922 shares during the last quarter. Xact Kapitalforvaltning AB purchased a new position in shares of Vanda Pharmaceuticals in the 2nd quarter worth approximately $240,000. Finally, PNC Financial Services Group Inc. grew its position in shares of Vanda Pharmaceuticals by 25.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 279,485 shares of the biopharmaceutical company’s stock worth $6,414,000 after buying an additional 55,911 shares during the last quarter. 99.33% of the stock is currently owned by institutional investors and hedge funds.
VNDA stock traded down $1.82 during trading on Monday, hitting $27.60. The company had a trading volume of 652,062 shares, compared to its average volume of 771,460. The company has a market capitalization of $1.54 billion, a PE ratio of -78.86, a P/E/G ratio of 4.00 and a beta of 0.87. Vanda Pharmaceuticals has a 52-week low of $13.30 and a 52-week high of $33.44.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Further Reading: What Factors Can Affect Return on Equity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.